Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Close Icon

Hot topics

Thought leadership

Research and development strategy

Close Icon

Events

Conferences 2020

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Get ahead with in-depth pharmaceutical competitive intelligence

Stay on top of the rapidly changing competitive landscape with detailed insight and intelligence on key industry, commercial, clinical, regulatory, and R&D events.

Master the marketplace

To succeed in the pharmaceutical marketplace, it’s vital to stay up to date with developments that can affect your business. Our competitive and market intelligence can give you all the credible, detailed information you need in one place.

What we offer

You can quickly access referenced information across global key industry developments in the pharmaceutical and medical technology markets with our easy-to-use solutions and expert analysts.

Build detailed competitive and market landscape analyses quickly, with access to global information on:

Drug and device development
Patient populations
Clinical trials
Drug and device patents
Market moving events
Patient-based sales forecasts

How it helps

We help you more accurately:

Prioritize pharmaceutical R&D spend by finding gaps and unmet needs through the analysis of competitors’ targets and R&D priorities
Understand disease epidemiology and disease sub-populations targeted in clinical development
Anticipate market changes through patent expiration tracking
Earmark who is entering or exiting your market via licensing or acquisition, as well as who is securing or providing funding
Project revenue for your pipeline and marketed drugs

Relevant products

Datamonitor Healthcare: data analysis and insight

Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.

Key benefits:

Prioritize market opportunities
Identify unmet needs
Make informed decisions

Scrip: industry news and insights

Key benefits:

Follow market developments
Go beyond the news
Hear from news makers

Biomedtracker: follow the drug development process

Track and assess key events that will impact a drug’s probability of technical success and approval.

Key benefits:

Stay up to date
Get ahead of the competition
Conference coverage

View all content

Scrip

A Positive Outlook For Deals, With Election Year Caveats

By Jessica Merrill 17 Feb 2020

Industry advisers at the BIO CEO & Investor meeting remained optimistic about the pharmaceutical deal environment in 2020 – even with the uncertainty around a looming US election year.

Topic BioPharmaceutical

View article
Scrip

Another Alzheimer's Setback As Roche And Lilly Drugs Fail

By Kevin Grogan 17 Feb 2020

As Biogen moves to file its controversial amyloid drug aducanumab for approval in the US, two similar investigational Alzheimer's drugs – Eli Lilly's solanezumab and Roche's gantenerumab – did not slow memory loss or cognitive decline in a rare, inherited form of the disease.

Topic Alzheimer's Disease

View article
Scrip

38th Annual J.P. Morgan Healthcare Conference Review

07 Feb 2020

Go inside the 2020 J.P. Morgan Healthcare Conference with exclusive reporting from Scrip. Explore the most important news from each day, and access exclusive, real-time interviews with pharma and biotech movers and shakers, and discover insights into the trends revealed at this year’s event.

Single report
Scrip

Gilead Joins Coronavirus Fray With Repurposed Antiviral

By Brian Yang 07 Feb 2020

US antiviral specialist Gilead is working to provide its experimental drug remdesivir to treat the China coronavirus, while other potential treatments and alliances continue to emerge, including between Wuhan-based BravoVax and US venture GeoVax.

Topic Coronavirus

View article
Scrip

GSK Joins Race To Tackle Coronavirus

By Kevin Grogan 07 Feb 2020

The pharma major is providing its adjuvant system, designed to enhance the body’s immune response, to help the Coalition for Epidemic Preparedness Innovations' efforts to accelerate the creation of a vaccine for the coronavirus strain that broke out in China and has spread to 24 countries.

Topic Coronavirus

View article
Scrip

Novel Virus Brings Novel Threats To Global Pharmaceutical Manufacturing

By Bowman Cox 07 Feb 2020

As coronavirus spreads into China’s manufacturing region, quarantines and travel restrictions challenge international flow of pharmaceuticals, ingredients and personnel.

Topic Coronavirus

View article
Scrip

Coronavirus Notebook: China Generic Antiviral Filed For Emergency Approval

By Brian Yang 07 Feb 2020

China is tightening oversight over suspected coronavirus cases, allowing hospitals to quarantine patients upon their first visit as confirmed infections surpass 20,000. Domestic firm Ascletis has meanwhile filed for the emergency approval of its generic version of AbbVie's Norvir (ritonavir) and a novel combo therapy.

Topic Coronavirus

View article
Scrip

FDA Responds To Coronavirus By Getting Out First Emergency-Use Novel Coronavirus Diagnostic

By Sue Darcey 07 Feb 2020

The US agency on 4 February issued its first Emergency Use Authorization of a 2019-novel coronavirus test by enabling emergency use of the Centers for Disease Control and Prevention’s 2019-nCoV Real-Time RT-PCR Diagnostic Panel. The move will allow use of the test at any CDC-qualified lab across the US.

Topic Coronavirus

View article
Scrip

Japan Pharma Unconcerned About Virus Impact - For Now

By Ian Haydock 07 Feb 2020

Spreading China outbreak not a point of focus for companies or analysts in quarterly results briefings.

Topic Coronavirus

View article
Scrip

Coronavirus Notebook: Regeneron, HHS To Develop Antibody

By Brian Yang 07 Feb 2020

Wuhan Institute of Pathology files patent over new use of Gilead's remdesivir and Regeneron expands collaboration with HHS to include 2019-nCoV.

Topic Coronavirus

View article
Scrip

Scrip Preview Pharma Trends for 2020

06 Feb 2020

For Scrip’s annual preview, our journalists asked over 80 industry executives and experts for their predictions of the major trends for 2020. From AI to M&A, gene therapy to the upcoming US election, here’s what to watch for as we begin this new decade.

Topic Biosimilars BioPharmaceutical

Single report
Biomedtracker, Meddevicetracker

38th Annual J.P. Morgan Healthcare Conference Review

03 Feb 2020

The 38th Annual J.P. Morgan Healthcare Conference has concluded, and Biomedtracker and Meddevicetracker were there to bring you the important outcomes from the largest and most informative annual healthcare investment symposium in the industry.

Single report
Scrip

China Coronavirus Cases Up Sharply As Pharma Rushes To Aid

By Brian Yang 30 Jan 2020

AbbVie’s HIV therapy Kaletra is now being used by the Chinese government to treat coronavirus-infected patients after a respiratory expert endorsed its use, while other pharma companies from Bayer to Innovent are showering support as China battles its worst virus outbreak since the SARS epidemic 17 years ago.

View article
Scrip

Atriva Fast Tracks Antiviral Candidate As Coronavirus Arrives In Germany

By Andrew McConaghie 30 Jan 2020

The antiviral specialist says MEK inhibitor could work against 2019-nCoV, but tests will take time.

Topic Coronovirus Vaccines

View article
Scrip

Coronavirus: Can Companies Achieve Vaccine Ambition?

By Andrew McConaghie 30 Jan 2020

As the death toll rises in China and new cases emerge in other countries, researchers are aiming to slash development times to generate a vaccine against the 2019-nCoV coronavirus.

Topic Coronovirus Research Vaccines

View article